Arkolith/Funds/Nan Fung Trinity

Nan Fung Trinity

CIK 1781880Hedge fund
Holdings as of Jun 30, 2026·disclosed Jul 24, 2026·~24-day 13F lag·13F-HR
Active Filer

Nan Fung Trinity holds a diversified book of 55 stocks worth $1.0B as of Q2 2026 (disclosed Jul 24, 2026, a ~45-day 13F lag). This quarter they opened Iren Ltd and trimmed Advanced Micro Devices. Their largest long position is Advanced Micro Devices at 7% of the equity book. Cloning the disclosed picks since 2024 would be +59% (+31.5%/yr). That is a simulation of the disclosed long book, not audited returns.

Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Build

Ask your agent what Nan Fung Trinity owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1781880/holdings"
Ask your agent
Use Arkolith to show NAN FUNG TRINITY's latest
holdings, largest changes, and filing provenance.
Opened
56
new positions
Added to
13
existing
Trimmed
6
reduced
Sold out
14
exited

Growth of $10,000: cloning the disclosed book

If you'd copied them
+59.5%
+31.5%/yr · since Nov '24
Their reported book
+35.2%
held from quarter-end
S&P 500
+26.0%
same window
$9K$10K$12K$14K$16KNov '24Mar '25Jul '25Nov '25Mar '26Jul '26
Nan Fung Trinity (copied at disclosure) S&P 500

Following at the filing date actually beat the quarter-end book by 24.3 points over this window.

Growth of $10,000 cloning Nan Fung Trinity's disclosed long 13F book, rebalanced on each filing date (so it reflects the ~45-day reporting lag, no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.

Concentration

Top-heavy: diversified book

Top 5 holdings
24%
Top 10 holdings
41%
Top 20 holdings
65%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

86% mapped to company sectors

Health Care
34%
ETF / fund or unclassified
14%
Information Technology
13%
Materials
13%
Consumer Discretionary
10%
Communication Services
8%
Real Estate
4%
Industrials
2%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought
Trimmed / exited

Funds with the most overlap

Other tracked managers holding the same core names as Nan Fung Trinity

Manager / fundShared namesTheir $ in those
BlackRock, Inc.73 / 55$622.7B
JPMORGAN CHASE & CO73 / 55$135.5B
MORGAN STANLEY73 / 55$125.3B
UBS Group AG73 / 55$39.8B
ROYAL BANK OF CANADA73 / 55$34.3B
BNP PARIBAS FINANCIAL MARKETS73 / 55$13.9B
GOLDMAN SACHS GROUP INC72 / 55$67.3B
OSAIC HOLDINGS, INC.72 / 55$2.9B

Ranked by how many of Nan Fung Trinity's top 55 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

55 positions
#SecurityValueShares% PortLast moveHistory
1Advanced Micro Devices Inc
COM
$67.8M116.7K
6.7%
−28%
Reduced · −45K sh
2Amcor PLC
COM NEW
$52.0M1.20M
5.1%
+7.5%
Added · +84K sh
3PPG Inds Inc
COM
$48.2M397.3K
4.8%
Held
4Ge Healthcare Technologies I
COMMON STOCK
$40.9M638.7K
4.0%
+203%
Added · +428K sh
5Nvidia Corporation
COM
$36.1M180.2K
3.6%
−22%
Reduced · −50K sh
6Home Depot Inc
COM
$35.2M99.9K
3.5%
+37%
Added · +27K sh
7KT Corp
SPONSORED ADR
$33.8M1.96M
3.3%
+0.3%
Added · +5K sh
8Ishares TR
MSCI INDONIA ETF
$33.7M2.98M
3.3%
+33%
Added · +745K sh
9Ishares TR
MBS ETF
$33.0M349.2K
3.3%
Held
10Owens Corning New
COM
$29.6M186.3K
2.9%
+37%
Added · +50K sh
11Unitedhealth Group Inc
COM
$28.4M68.3K
2.8%
−34%
Reduced · −36K sh
12Air Products And Chemicals I
COM
$28.3M96.7K
2.8%
Held
13Ishares TR
CORE S&P MCP ETF
$27.7M359.0K
2.7%
Held
14America Movil SAB De CV
SPON ADS RP CL B
$27.4M1.06M
2.7%
−20%
Reduced · −267K sh
15Mirum Pharmaceuticals Inc
COM
$27.2M232.7K
2.7%
Held
16Danaher Corp Del
COM
$24.1M126.5K
2.4%
+28%
Added · +28K sh
17Trevi Therapeutics Inc
COM
$22.6M1.21M
2.2%
+6.2%
Added · +71K sh
18Meta Platforms Inc
CL A
$21.0M37.4K
2.1%
+146%
Added · +22K sh
19Protagonist Therapeutics Inc
COM
$19.7M160.7K
1.9%
Held
20Abivax Sa
SPONSORED ADS
$18.9M142.1K
1.9%
+10%
Added · +13K sh
21SPDR Series Trust
ST STR SP HOME
$17.9M155.0K
1.8%
Held
22Jd.com Inc
SPON ADS CL A
$16.6M649.7K
1.6%
Held
23Bridgebio Pharma Inc
COM
$16.3M219.2K
1.6%
Held
24MP Materials Corp
COM CL A
$15.9M283.1K
1.6%
Held
25PDD Holdings Inc
SPONSORED ADS
$15.8M207.7K
1.6%
+36%
Added · +55K sh
26Scholar Rock Hldg Corp
COM
$15.7M285.5K
1.6%
Held
27Warner Bros Discovery Inc
COM SER A
$15.3M575.7K
1.5%
Held
28Immunome Inc
COM
$15.1M714.6K
1.5%
Held
29Xenon Pharmaceuticals Inc
COM
$15.0M247.8K
1.5%
Held
30Iren Limited
ORDINARY SHARES
$13.5M295.0K
1.3%
New
New position
31Kura Oncology Inc
COM
$12.9M1.17M
1.3%
+10%
Added · +110K sh
32Bicara Therapeutics Inc
COM
$12.7M427.9K
1.3%
Held
33Alexandria Real Estate Eq In
COM
$12.6M239.0K
1.2%
Held
34Honeywell Intl Inc
COM
$12.3M55.1K
1.2%
New
New position
35Honeywell Aerospace Inc
COM
$12.2M55.1K
1.2%
New
New position
36Vor Biopharma Inc
COM NEW
$11.9M646.5K
1.2%
New
New position
37Flex Ltd
ORD
$11.7M72.3K
1.2%
New
New position
38CRH PLC
ORD
$11.4M106.7K
1.1%
New
New position
39Savara Inc
COM
$11.3M1.84M
1.1%
Held
40Celcuity Inc
COM
$10.9M103.8K
1.1%
Held
41BXP Inc
COM
$8.1M121.9K
0.8%
Held
42Kilroy Realty Corp
COM
$7.9M210.8K
0.8%
Held
43Vaxcyte Inc
COM
$7.1M122.9K
0.7%
Held
44SL Green Rlty Corp
COM
$6.9M132.5K
0.7%
−2.4%
Reduced · −3K sh
45Zai Lab Ltd
ADR
$6.6M346.5K
0.6%
Held
46Abeona Therapeutics Inc
COM NEW
$5.9M956.8K
0.6%
Held
47Vornado Rlty TR
SH BEN INT
$5.7M143.8K
0.6%
Held
48Uniqure NV
SHS
$5.3M115.5K
0.5%
Held
49Climb Bio Inc
COM
$4.7M360.7K
0.5%
−14%
Reduced · −60K sh
50Biocryst Pharmaceuticals Inc
COM
$4.5M450.0K
0.4%
New
New position
Showing 50 of 55 positions

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q2 2026Jun 30, 2026Jul 24, 202655$1.0B13F-HR
Q1 2026Mar 31, 2026May 5, 202662$910.6M13F-HR
Q4 2025Dec 31, 2025Feb 4, 202678$1.3B13F-HR
Q3 2025Sep 30, 2025Nov 4, 202571$1.0B13F-HR
Q2 2025Jun 30, 2025Aug 8, 202559$835.8M13F-HR
Q1 2025Mar 31, 2025May 8, 202539$630.5M13F-HR
Q4 2024Dec 31, 2024Feb 4, 202530$489.7M13F-HR
Q3 2024Sep 30, 2024Nov 13, 202426$528.4M13F-HR

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.